Related Experiment Video

Updated: Apr 16, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.6K

Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence

I Gonzalez-Valdes1, I Hidalgo1, A Bujarrabal1

  • 1Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain.

Nature Communications
|March 10, 2015
PubMed

Insights

The epigenetic regulator Bmi1 prevents dilated cardiomyopathy (DCM) by suppressing cardiac senescence. Loss of Bmi1 accelerates DCM, while its overexpression protects the heart, suggesting therapeutic potential for cardiac rejuvenation.

Area of Science:

  • Cardiology
  • Epigenetics
  • Aging Biology

Background:

  • Dilated cardiomyopathy (DCM) is a primary cause of heart failure and a leading reason for heart transplantation.
  • Cardiac senescence, a state of irreversible cell cycle arrest, contributes to cardiac dysfunction.

Purpose of the Study:

  • To investigate the role of the epigenetic regulator Bmi1 in the development and progression of DCM.
  • To explore the therapeutic potential of targeting Bmi1 and cardiac senescence for heart regeneration.

Main Methods:

  • Cardiac-specific Bmi1 deletion and overexpression in mouse models.
  • Transcriptome analysis of human and mouse DCM samples.
  • Genetic manipulation of p16(INK4a) levels.
  • Parabiosis assays to assess paracrine signaling.

Main Results:

  • Cardiac-specific Bmi1 deletion induced DCM, lung congestion, and heart failure.
  • Bmi1 overexpression protected against cardiac hypertrophy.
  • Derepression of p16(INK4a) and induction of senescence-associated secretory phenotype (SASP) correlated with impaired ventricular function in DCM.
  • Genetic reduction of p16(INK4a) ameliorated DCM pathology in Bmi1-deficient hearts.
  • The senescence response in DCM did not transmit to healthy hearts via parabiosis.

Conclusions:

  • Bmi1 acts as a crucial repressor of cardiac senescence, protecting against DCM.
  • Targeting p16(INK4a) and associated senescence pathways offers a potential strategy for treating DCM.
  • These findings highlight Bmi1 and senescence as key factors in cardiac aging and suggest avenues for cardiac rejuvenation therapies.

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.5K
Simultaneous Assessment of Cardiomyocyte DNA Synthesis and Ploidy: A Method to Assist Quantification of Cardiomyocyte Regeneration and Turnover08:03

Simultaneous Assessment of Cardiomyocyte DNA Synthesis and Ploidy: A Method to Assist Quantification of Cardiomyocyte Regeneration and Turnover

Published on: May 23, 2016

10.9K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K